orcinol has been researched along with Osteoporosis in 2 studies
*Osteoporosis: Reduction of bone mass without alteration in the composition of bone, leading to fractures. Primary osteoporosis can be of two major types: postmenopausal osteoporosis (OSTEOPOROSIS, POSTMENOPAUSAL) and age-related or senile osteoporosis. [MeSH]
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gong, W; Liu, M; Qin, L; Wang, Y; Xiang, L; Zhang, Q; Zhao, Q; Zheng, C | 1 |
| Cheng, G; He, XY; Liu, Y; Liu, YL; Qin, LP; Sun, P; Wang, TJ; Yao, LP; Yu, Y; Zhang, QL; Zhang, QY; Zhao, WL | 1 |
2 other study(ies) available for orcinol and Osteoporosis
| Article | Year |
|---|---|
Orcinol Glucoside Improves Senile Osteoporosis through Attenuating Oxidative Stress and Autophagy of Osteoclast via Activating Nrf2/Keap1 and mTOR Signaling Pathway.
Topics: Animals; Autophagy; Bone Resorption; Glucosides; Hydrogen Peroxide; Kelch-Like ECH-Associated Protein 1; Mice; NF-E2-Related Factor 2; Osteoclasts; Osteoporosis; Oxidative Stress; RANK Ligand; Resorcinols; Signal Transduction; TOR Serine-Threonine Kinases | 2022 |
Orcinol glucoside targeted p38 as an agonist to promote osteogenesis and protect glucocorticoid-induced osteoporosis.
Topics: Animals; Glucocorticoids; Glucosides; Mice; Molecular Docking Simulation; Osteogenesis; Osteoporosis | 2023 |